Now, it’s worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 194% for ...
Cidara Therapeutics (CDTX) stock rocketed higher on Friday after the biotechnology company announced it will be acquired by ...
Cidara Therapeutics (CDTX) stock surge 100% as Merck acquires biotech for $9.2B at $221.50 per share, triple its previous ...
Wondering if Merck stock is truly a bargain or just priced for perfection? You are not alone. Let's dig into what the numbers ...
Merck & Co., Inc. acquires Cidara Therapeutics, Inc. for $9.2bn, boosting its pipeline with CD388's strong flu data. Click ...
Merck & Co. Inc. (NYSE: MRK) on Friday agreed to acquire Cidara Therapeutics, Inc. (NASDAQ: CDTX) for $221.50 per share in ...
Shares rise 8.5% on enlicitide decanoate Phase 3 data showing LDL reduction. Q3 earnings beat at $2.58/share with $17.3B ...
Merck will pay $221.50 a share in cash for Cidara in a tender offer, more the twice Thursday’s closing price, for a total ...
Antipodes Partners recently published its “Antipodes Global Value Strategy” third-quarter 2025 investor letter, highlighting ...
Investing.com-- Merck & Company Inc (NYSE: MRK ) is close to a deal to buy flu treatment maker Cidara Therapeutics Inc (NASDAQ: CDTX) after pulling ahead of rivals in a bidding war for the firm, the ...
In recent days, Merck announced pivotal Phase 3 trial results showing its once-daily oral PCSK9 inhibitor, enlicitide, reduced low-density lipoprotein cholesterol by more than half in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback